NEW SCIENTIFIC PUBLICATION FURTHER SUPPORTS BIOMARK’S ASSAY

Vancouver, British Columbia – (August 27th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Predictive value and clinical significance of increased SSAT-1 activity in healthy adults” has been published in the peer-reviewed journal Future Science OA.

 

Rashid Ahmed, President and CEO, says, “This is our latest trilogy SSAT-1(Spermidine/spermine N1-acetyltransferase ) publication and we would like to acknowledge the contributions made by a dedicated team of clinicians, scientists and researchers. This publication provides additional scientific validation and evidence that one of our technology platforms (SSAT1 assay) has important clinical applications in the cancer diagnostic space. In our previous clinical studies, we observed that some healthy volunteers (“outliers”) had, higher than expected acetylated amantadine (AA) concentration. This was intriguing and we subsequently conducted detailed clinical assessments. Analysis of the ‘outliers’ observed in previous studies using the amantadine test revealed that a large number were at risk or developed cancer, suggesting that the test can predict the occurrence of cancer. Monitoring of urinary AA concentration combined with clinical and hematological characteristics could be established as a useful tool for purposes of screening and follow-up for cancer in high-risk populations. Our findings in ‘outliers’ support usefulness of amantadine assay as a screening or surveillance test in populations considered at high risk for developing cancer. It is also possible that this test could be used for monitoring patients after curative surgical or chemoradiation therapy to assess eradication of the tumor. Also, in follow-up, it could possibly detect proliferation of new cancer cells (relapse)”.

 

“We are on track to publish additional peer reviewed papers and present abstracts or posters in the near term on significant discoveries that we have strategically invested resources over the past few years.” says Rashid.

 

The paper is available through open access at https://www.future- science.com/doi/full/10.2144/fsoa-2019-0023 and on https://www.ncbi.nlm.nih.gov/pubmed/31428447. BioMark encourages subscription to Future Science for individuals and institutions interested in keeping abreast of new developments in biotechnology and medicine.

 

About Future Science OA

Launched in March 2015, Future Science OA is the inaugural gold open access journal from Future Science Group. It publishes articles covering research of application to human health and utilizes a CC-BY license. Future Science OA embraces the importance of publishing all good-quality research with the potential to further the progress of medical science. Negative and early-phase research will be considered. The journal also features review articles, editorials and perspectives, providing readers with a leading source of commentary and analysis.

About Future Science Group

Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological, and scientific research. FSG’s portfolio includes two imprints, Future Science and Future Medicine. Both publish eBooks and journals. In addition to this core publishing business FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine. The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards.

For all queries, contact Laura Dormer email to: l.dormer@futuremedicine.com>

Press Release – NEW SCIENTIFIC PUBLICATION FURTHER SUPPORTS BIOMARK’S ASSAY

BIOMARK’S LIQUID BIOPSY SCIENTIFIC PAPER TO BE FEATURED AS COVER ON CANCERS UPCOMING ISSUE

Vancouver, British Columbia – (August 19th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Liquid Biopsy in Lung Cancer Screening: The Contribution of Metabolomics. Results of A Pilot Study” will be on cover of Cancers.

 

Rashid Ahmed, President and CEO, says, “This latest paper that was published a few days ago paper has been selected by the editors of the journal as the cover of the forthcoming issue. The issue cover will be displayed on the issue page: https://www.mdpi.com/2072-6694/11, and promoted in the issue released notification which will be sent to the journal subscribers together with the table of contents. I would like to thank and acknowledge the team for their excellent contribution that resulted in recognition of this manuscript.”

 

The paper is available through : https://www.mdpi.com/2072-6694/11/8/1069 and or at https://www.ncbi.nlm.nih.gov/pubmed/31362354

 

About Cancers

Cancers (ISSN 2072-6694) is an international, peer-reviewed open access journal on oncology. It publishes article types including Research Papers, Reviews, Editorials, Communications, etc. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. The full experimental details must be provided so that the results can be reproduced.

There is, in addition, a unique feature of this journal: we accept studies showing meaningful but negative results. While there are many journals that focus on cancer studies, none of them actively accepts negative results. As a result, most negative data end up not being in the public domain even if the data were meaningfully negative and the study well designed. By accepting those negative results, our journal encourages scientists to share those data so that they would not need to repeat the experiments that somebody else has already done.

 

Scope of Journal

We publish high-quality articles including basic, translational, and clinical studies on all tumor types (https://medlineplus.gov/cancers.html).

Press Release – BIOMARK’S LIQUID BIOPSY SCIENTIFIC PAPER TO BE FEATURED AS COVER ON CANCERS UPCOMING ISSUE

NEW ADVANCES IN LIQUID BIOPSY TO INCREASE BIOMARK’S ASSAY PERFORMANCE

Vancouver, British Columbia – (August 13th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Liquid Biopsy in Lung Cancer Screening: The Contribution of Metabolomics. Results of A Pilot Study” has been published in the peer-reviewed journal Cancers.

 

Rashid Ahmed, President and CEO, says, “This latest publication demonstrates our ability to engage an international team consisting of leading clinicians, scientists, researchers and data scientists in discovery and translational research for the development of a lung cancer diagnostic assay. The cross disciplinary team conducted a successful pilot study that provides evidence that its SSAT-1 (Spermidine Spermine Acetyl Transferase) assay signal is amplified, and the tissue specificity is increased by incorporating a panel of distinct metabolites.  When used in conjunction with the SSAT-1/polyamine pathway, these metabolites may provide the specificity required for diagnosing lung cancer from other cancer types and could be used as a promising lung diagnostic and treatment monitoring tool. We are excited about the possibility of increasing tissue specificity for other cancers by using specific metabolites to complement our SSAT-1 assay”.

 

The international team consisted of  Drs Christian Rolfo (Marlene and Stewart Greenebaum Comprehensive Cancer Centre, University of Maryland, School of Medicine Baltimore), Parveen Shahida Akhtar(Department of Medical Oncology, National Institute of Cancer Research & Hospital,  Dhaka, Bangladesh , Dr. Andrew Maksymiuk (CancerCare Manitoba),  Daniel Sitar (Department of Internal Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba), Bram Ramjiawan (Asper Clinical Research Institute & Office of Clinical Research, St. Boniface Hospital, Winnipeg, Manitoba), Paramjit Tappia (Asper Clinical Research Institute & Office of Clinical Research, St. Boniface Hospital, Winnipeg, Manitoba), Sandeep Singhal (Columbia University Medical Center, New York ) and Alessandro Russo (Medical Oncology Unit A.O. Papardo & Department of Human Pathology, University of Messina).

 

The paper is available through : https://www.mdpi.com/2072-6694/11/8/1069 and or at https://www.ncbi.nlm.nih.gov/pubmed/31362354

 

About Cancers

Cancers (ISSN 2072-6694) is an international, peer-reviewed open access journal on oncology. It publishes article types including Research Papers, Reviews, Editorials, Communications, etc. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. The full experimental details must be provided so that the results can be reproduced.

There is, in addition, a unique feature of this journal: we accept studies showing meaningful but negative results. While there are many journals that focus on cancer studies, none of them actively accepts negative results. As a result, most negative data end up not being in the public domain even if the data were meaningfully negative and the study well designed. By accepting those negative results, our journal encourages scientists to share those data so that they would not need to repeat the experiments that somebody else has already done.

Scope of Journal

We publish high-quality articles including basic, translational, and clinical studies on all tumor types (https://medlineplus.gov/cancers.html).

Press Release – NEW ADVANCES IN LIQUID BIOPSY TO INCREASE BIOMARK’S ASSAY PERFORMANCE

The University of Maryland School of Medicine Enters Research Collaboration with BioMark Diagnostics

Vancouver, British Columbia – (June 26, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that BioMark and the University of Maryland School of Medicine (UMSOM) have entered into a collaboration related to the discovery and validation of biomarkers using a combinatorial technology approach. This collaboration follows several productive meetings between BioMark and UMSOM clinicians and lab service specialists as well as employees in UMSOM’s offices of technology transfer, research affairs, and research and development.

 

The initial primary area of focus will be to confirm through a proof of concept study the clinical utility of using tumour biomarker(s) developed by BioMark initially in accelerating assessment following glioblastoma multiforme (GBM) resection and correlating it to existing anatomical imaging tests for confirmation. Drs Graeme Woodworth -Professor, Department of Neurosurgery, Director, Brain Tumor Treatment and Research Center Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine) and Chetan Bettegowda – Associate Professor of Neurosurgery and Oncology and Director of Meningioma Centre Department of Neurosurgery Johns Hopkins will be principal investigators (PIs) on this study. The study will commence after ethics approval is granted. A Canadian team will also be conducting a parallel and augmenting study at the University of Manitoba and CancerCare Manitoba sites under the CHRP grant received in April 2019.

 

A second area of focus will be an assay validation of BioMark’s lung cancer liquid biopsy for utilization in early lung cancer screening initiatives and measuring response to treatment. Dr. Christian Rolfo (Professor at the Department of Medicine at the University of Maryland School of Medicine, Director, Thoracic Medical Oncology, and Director, Early Phase Clinical Trials at University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center) will be the PI leading most of the studies (prospective, retrospective and longitudinal) related to lung cancer.

 

“BioMark is excited to collaborate with the University of Maryland School of Medicine and to be part of Maryland’s dynamic medical technology ecosystem. This is a significant opportunity and moment for our company,” said Rashid Ahmed, CEO of BioMark. “In addition, BioMark is planning to set up operations in Baltimore, and the current designated site is located at 875 Hollins Street Suite 102-G Baltimore MD 21201. More details will be released as planned progress is made.”

 

 

About the University of Maryland School of Medicine

 

The University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It is dedicated to providing excellence in biomedical education, basic and clinical research, quality patient care and service to improve the health of the citizens of Maryland and beyond. UMSOM is committed to the education and training of medical, MD/PhD, graduate, physical therapy and medical and research technology students. The university recruits and develops faculty to serve as exemplary role models for their students.

 

World Class Research

UMSOM is one of the fastest growing, top-tier biomedical research enterprises in the world. It has 43 academic departments, centers, institutes, and programs, and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine, and a distinguished recipient of the Albert E. Lasker Award in Medical Research.

 

The School of Medicine faculty, which ranks as the 8th-highest public medical school in research productivity, is an innovator in translational medicine with 600 active patents and 24 start-up companies. The School works locally, nationally, and globally with research and treatment facilities in 36 countries.

 

Compassionate Patient-Centered Care

With an operating budget of more than $1 billion, UMSOM works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically-based care for more than 1.2 million patients each year.

 

Educational Excellence

UMSOM has over 2,500 students, residents, and fellows, and nearly $450 million in extramural funding, with more than half of its academic departments ranked in the top 20 among all public medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has nearly 7,000 total employees.

 

Economic Impact

The combined School and Medical System (“University of Maryland Medicine”) has a total budget of $5 billion and an economic impact of nearly $15 billion on the state and local community.

 

Further information about University of Maryland School of Medicine is available under its official website: https://www.medschool.umaryland.edu/

News Release – The University of Maryland School of Medicine Enters Research Collaboration with BioMark Diagnostics